J.C. Reichert
University of Würzburg
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J.C. Reichert.
American Journal of Sports Medicine | 2011
U. Schneider; Lars Rackwitz; Stefan Andereya; Sebastian Siebenlist; Florian Fensky; J.C. Reichert; Ingo Löer; Thomas Barthel; Maximilian Rudert; Ulrich Nöth
Background: The Cartilage Regeneration System (CaReS) is a novel matrix-associated autologous chondrocyte implantation (ACI) technique for the treatment of chondral and osteochondral lesions (Outerbridge grades III and IV). For this technology, no expansion of the chondrocytes in a monolayer culture is needed, and a homogeneous cell distribution within the gel is guaranteed. Purpose: To report a prospective multicenter study of matrix-associated ACI of the knee using a new type I collagen hydrogel (CaReS). Study Design: Case series; Level of evidence, 4. Methods: From 2003 to 2008, 116 patients (49 women and 67 men; mean age, 32.5 ± 8.9 years) had CaReS implantation of the knee in 9 different centers. On the basis of the International Cartilage Repair Society (ICRS) Cartilage Injury Evaluation Package 2000, the International Knee Documentation Committee (IKDC) score, pain score (visual analog scale [VAS]), SF-36 score, overall treatment satisfaction and the IKDC functional status were evaluated. Patient follow-up was performed at 3, 6, and 12 months after surgery and annually thereafter. Mean follow-up was 30.2 ± 17.4 months (range, 12-60 months). There were 67 defects of the medial condyle, 14 of the lateral, 22 of the patella/trochlea, and 3 of the tibial plateau, and 10 patients had 2 lesions. The mean defect size was 5.4 ± 2.4 cm2. Thirty percent of the defects were <4 cm2 and 70% were >4 cm2. Results: The IKDC score improved significantly from 42.4 ± 13.8 preoperatively to 70.5 ± 18.7 (P < .001) at latest follow-up. Global pain level significantly decreased (P < .001) from 6.7 ± 2.2 preoperatively to 3.2 ± 3.1 at latest follow-up. There also was a significant increase of both components of the SF-36 score. The overall treatment satisfaction was judged as very good or good in 88% by the surgeon and 80% by the patient. The IKDC functional knee status was grade I in 23.4%, II in 56.3%, III in 17.2%, and IV in 3.1% of the patients. Conclusion: Matrix-associated ACI employing the CaReS technology for the treatment of chondral or osteochondral defects of the knee is a safe and clinically effective treatment that yields significant functional improvement and improvement in pain level. However, further investigation is necessary to determine the long-term viability and clinical outcome of this procedure.
Orthopade | 2012
J.C. Reichert; Devakara R. Epari; Martin E. Wullschleger; Arne Berner; Siamak Saifzadeh; Ulrich Nöth; Ian C. Dickinson; Michael Schuetz; Dietmar W. Hutmacher
Well-established therapies for bone defects are restricted to bone grafts which face significant disadvantages (limited availability, donor site morbidity, insufficient integration). Therefore, the objective was to develop an alternative approach investigating the regenerative potential of medical grade polycaprolactone-tricalcium phosphate (mPCL-TCP) and silk-hydroxyapatite (silk-HA) scaffolds.Critical sized ovine tibial defects were created and stabilized. Defects were left untreated, reconstructed with autologous bone grafts (ABG) and mPCL-TCP or silk-HA scaffolds. Animals were observed for 12 weeks. X-ray analysis, torsion testing and quantitative computed tomography (CT) analyses were performed. Radiological analysis confirmed the critical nature of the defects. Full defect bridging occurred in the autograft and partial bridging in the mPCL-TCP group. Only little bone formation was observed with silk-HA scaffolds. Biomechanical testing revealed a higher torsional moment/stiffness (p < 0.05) and CT analysis a significantly higher amount of bone formation for the ABG group when compared to the silk-HA group. No significant difference was determined between the ABG and mPCL-TCP groups. The results of this study suggest that mPCL-TCP scaffolds combined can serve as an alternative to autologous bone grafting in long bone defect regeneration. The combination of mPCL-TCP with osteogenic cells or growth factors represents an attractive means to further enhance bone formation.
Orthopade | 2012
J.C. Reichert; Devakar Epari; Martin E. Wullschleger; Arne Berner; Siamak Saifzadeh; Ulrich Nöth; Ian C. Dickinson; Michael Schuetz; Dietmar W. Hutmacher
Well-established therapies for bone defects are restricted to bone grafts which face significant disadvantages (limited availability, donor site morbidity, insufficient integration). Therefore, the objective was to develop an alternative approach investigating the regenerative potential of medical grade polycaprolactone-tricalcium phosphate (mPCL-TCP) and silk-hydroxyapatite (silk-HA) scaffolds.Critical sized ovine tibial defects were created and stabilized. Defects were left untreated, reconstructed with autologous bone grafts (ABG) and mPCL-TCP or silk-HA scaffolds. Animals were observed for 12 weeks. X-ray analysis, torsion testing and quantitative computed tomography (CT) analyses were performed. Radiological analysis confirmed the critical nature of the defects. Full defect bridging occurred in the autograft and partial bridging in the mPCL-TCP group. Only little bone formation was observed with silk-HA scaffolds. Biomechanical testing revealed a higher torsional moment/stiffness (p < 0.05) and CT analysis a significantly higher amount of bone formation for the ABG group when compared to the silk-HA group. No significant difference was determined between the ABG and mPCL-TCP groups. The results of this study suggest that mPCL-TCP scaffolds combined can serve as an alternative to autologous bone grafting in long bone defect regeneration. The combination of mPCL-TCP with osteogenic cells or growth factors represents an attractive means to further enhance bone formation.
Advanced Drug Delivery Reviews | 2013
Boris Michael Holzapfel; J.C. Reichert; Jan-Thorsten Schantz; Uwe Gbureck; Lars Rackwitz; Ulrich Nöth; Franz Jakob; Maximilian Rudert; Jürgen Groll; Dietmar W. Hutmacher
Institute of Health and Biomedical Innovation; Science & Engineering Faculty | 2013
Arne Berner; J.C. Reichert; Maria A. Woodruff; Siamak Saifzadeh; Anthony Morris; Devakar Epari; Michael Nerlich; Michael Schuetz; Dietmar W. Hutmacher
Orthopade | 2012
L. Rackwitz; U. Schneider; S. Andereya; S. Siebenlist; J.C. Reichert; F. Fensky; J. Arnholdt; I. Löer; Grossstück R; W. Zinser; T. Barthel; Maximilian Rudert; Ulrich Nöth
Orthopade | 2012
L. Rackwitz; U. Schneider; S. Andereya; S. Siebenlist; J.C. Reichert; F. Fensky; J. Arnhold; I. Löer; R. Großstück; W. Zinser; T. Barthel; Maximilian Rudert; Ulrich Nöth
Archive | 2012
J.C. Reichert; Dietmar W. Hutmacher
Orthopade | 2018
L. Rackwitz; J.C. Reichert; M. Haversath; Ulrich Nöth; Marcus Jäger
School of Biomedical Sciences; Faculty of Health; Institute of Health and Biomedical Innovation | 2017
Vmc Quent; Anna Taubenberger; J.C. Reichert; Laure Martine; Judith A. Clements; Dietmar W. Hutmacher; Daniela Loessner